Repare Therapeutics Inc. Stock Price, News & Analysis

Repare Therapeutics reported Q3 2022 financial results, achieving a net income of $75.5 million, or $1.71 per diluted share, compared to a net loss of $30.9 million the previous year. The company holds $370.4 million in cash, sufficient to fund operations into 2026. Key developments include advancing RP-6306 in Phase 1 trials, with early data expected in H1 2023, and a collaboration with Roche for camonsertib, which includes a $125 million upfront payment and potential total milestone payments up to $1.172 billion.

Repare Therapeutics Inc. (NASDAQ: RPTX) has announced participation at two upcoming investor conferences in November 2022. The first is the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 at 10:00 a.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:00 p.m. ET, taking place in New York, NY. Investors can access live webcasts of both events on the Company’s website, with replays available for 90 days. Repare focuses on precision oncology and utilizes its proprietary SNIPRx® platform for novel cancer therapies.

Repare Therapeutics Inc. (NASDAQ: RPTX) will participate in two investor conferences in September 2022. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 2:55 p.m. ET in New York. The second is the Guggenheim Nantucket Therapeutics Conference on September 28 at 8:00 a.m. ET in Nantucket, MA. Live webcasts will be available on the company’s website, and replays will be accessible for 90 days. Repare focuses on precision oncology, utilizing its SNIPRx® platform to develop targeted cancer therapies.

Repare Therapeutics has signed a worldwide license and collaboration agreement with Roche for camonsertib (RP-3500) aimed at advanced solid tumors. Repare received a $125 million upfront payment and could earn up to $1.172 billion in milestones, plus royalties on global sales. The company expects clinical data for RP-6306 in early 2023, having initiated IND-enabling studies for RP-2119. Financial results show a net loss of $38.1 million for Q2 2022, up from $26.3 million in Q2 2021, despite increased R&D investments aimed at advancing its oncology pipeline.

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 03:20 p.m. PT. The event will take place in Rancho Palos Verdes, CA. A live webcast will be available on the Company’s website, with an archived replay for 90 days. Repare specializes in cancer therapies using its SNIPRx® platform, focusing on genomic instability and DNA damage repair, and is currently developed leading products like camonsertib (RP-3500) and RP-6306.

Repare Therapeutics has entered a worldwide license and collaboration agreement with Roche for the development of camonsertib (RP-3500), a selective ATR inhibitor targeting specific tumors. Repare will receive a $125 million upfront and could earn up to $1.2 billion in potential milestones and royalties. Roche will lead development, utilizing its expertise to expand treatment options. A conference call will be held today at 5:00 p.m. EDT to discuss this collaboration.

Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in the virtual 2022 Guggenheim Synthetic Lethality Day on May 16, 2022, at 9:00 a.m. ET. Senior management will engage in a fireside chat, providing insights into their precision oncology strategies. Interested parties can access a live webcast via the Investor section on their website, with an archived replay available for 90 days post-event. Repare is known for its innovative SNIPRx® platform focusing on synthetic lethality in cancer therapeutics development.

Repare Therapeutics Inc. (Nasdaq: RPTX) reported significant advancements in its RP-3500 program and showcased promising clinical data from the Phase 1/2 TRESR Trial at the 2022 AACR Annual Meeting. The trial demonstrated a 75% clinical benefit rate (CBR) in advanced ovarian cancer patients and 43% CBR across various solid tumors. Financially, the company reported cash reserves of $311.7 million but registered a net loss of $34.8 million for Q1 2022, reflecting increased R&D expenses. Repare anticipates further updates on camonsertib’s potential later in the year.

Repare Therapeutics has announced promising preclinical data that positions RP-6306, a first-in-class PKMYT1 inhibitor, as a potential treatment for CCNE1-amplified cancers. This data was published in Nature and shows significant tumor growth inhibition in vivo. Currently in Phase 1 clinical trials, RP-6306 is being studied both as a monotherapy and in combination with gemcitabine and FOLFIRI for advanced solid tumors. The SNIPRx platform played a pivotal role in identifying this novel therapeutic target, underscoring Repare's innovative capabilities.